Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Hillis

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Pharmacoeconomics|July 17, 2022
The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in CanadaChristopher Hillis, Colin Vicente, Graeme Ball
Leukemia & Lymphoma|September 17, 2015
Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysisChatree Chai-Adisaksopha, Wilson Lam, Christopher Hillis
Current Oncology Reports|August 3, 2021
Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial FibrillationMaude Sestier, Christopher Hillis, Graeme Fraser, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 2, 2025
Diagnosis and management of iron deficiency in femalesMichelle Sholzberg, Christopher Hillis, Mark Crowther, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 11, 2025
Michelle Sholzberg, Christopher Hillis, Mark Crowther, et al.
Current Oncology (Toronto, Ont.)|March 28, 2023
Optimizing Cancer Survivorship Care: Examination of Factors Associated with Transition to Primary CareSom D Mukherjee, Daryl Bainbridge, Christopher Hillis, et al.
Heart (British Cardiac Society)|July 1, 2021
Response to 'Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors'Darryl Leong, Christopher Hillis, Nazanin Aghel, et al.
Blood Advances|January 4, 2018
Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysisFrançois Caron, Darryl P Leong, Christopher Hillis, et al.
BMC Hematology|June 10, 2016
A systematic review of using and reporting survival analyses in acute lymphoblastic leukemia literatureChatree Chai-Adisaksopha, Alfonso Iorio, Christopher Hillis, et al.
Thrombosis and Haemostasis|May 29, 2015
Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysisChatree Chai-Adisaksopha, Christopher Hillis, Manuel Monreal, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Pharmacoeconomics|July 17, 2022
The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in CanadaChristopher Hillis, Colin Vicente, Graeme Ball
Leukemia & Lymphoma|September 17, 2015
Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysisChatree Chai-Adisaksopha, Wilson Lam, Christopher Hillis
Current Oncology Reports|August 3, 2021
Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial FibrillationMaude Sestier, Christopher Hillis, Graeme Fraser, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 2, 2025
Diagnosis and management of iron deficiency in femalesMichelle Sholzberg, Christopher Hillis, Mark Crowther, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 11, 2025
Michelle Sholzberg, Christopher Hillis, Mark Crowther, et al.
Current Oncology (Toronto, Ont.)|March 28, 2023
Optimizing Cancer Survivorship Care: Examination of Factors Associated with Transition to Primary CareSom D Mukherjee, Daryl Bainbridge, Christopher Hillis, et al.
Heart (British Cardiac Society)|July 1, 2021
Response to 'Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors'Darryl Leong, Christopher Hillis, Nazanin Aghel, et al.
Blood Advances|January 4, 2018
Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysisFrançois Caron, Darryl P Leong, Christopher Hillis, et al.
BMC Hematology|June 10, 2016
A systematic review of using and reporting survival analyses in acute lymphoblastic leukemia literatureChatree Chai-Adisaksopha, Alfonso Iorio, Christopher Hillis, et al.
Thrombosis and Haemostasis|May 29, 2015
Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysisChatree Chai-Adisaksopha, Christopher Hillis, Manuel Monreal, et al.
Pageof 4